X4 Pharmaceuticals, Inc. (XFOR)
XFOR Stock Price Chart
Explore X4 Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze XFOR price movements and trends.
XFOR Company Profile
Discover essential business fundamentals and corporate details for X4 Pharmaceuticals, Inc. (XFOR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
16 Nov 2017
Employees
143.00
Website
https://www.x4pharma.comCEO
Paula Ragan
Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
XFOR Financial Timeline
Browse a chronological timeline of X4 Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Apr 2026
Upcoming earnings on 12 Nov 2025
EPS estimate is -$0.87.
Earnings released on 8 Aug 2025
EPS came in at -$3.47 surpassing the estimated -$4.53 by +23.40%, while revenue for the quarter reached $1.97M , missing expectations by -11.38%.
Earnings released on 1 May 2025
EPS came in at $0.04 surpassing the estimated -$4.13 by +100.97%, while revenue for the quarter reached $28.81M , beating expectations by +1.42K%.
Stock split effective on 28 Apr 2025
Shares were split 1 : 30 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 25 Mar 2025
EPS came in at -$6.01 falling short of the estimated -$5.11 by -17.61%, while revenue for the quarter reached $1.43M , missing expectations by -35.82%.
Earnings released on 13 Nov 2024
EPS came in at -$0.18 falling short of the estimated -$0.17 by -5.88%, while revenue for the quarter reached $560.00K , missing expectations by -44.97%.
Earnings released on 8 Aug 2024
EPS came in at -$0.07 falling short of the estimated -$0.05 by -40.00%, while revenue for the quarter reached $563.00K , beating expectations by +101.07%.
Earnings released on 7 May 2024
EPS came in at -$0.26 falling short of the estimated -$0.17 by -52.94%.
Earnings released on 21 Mar 2024
EPS came in at -$0.10 surpassing the estimated -$0.15 by +33.33%, while revenue for the quarter reached $3.06M .
Earnings released on 9 Nov 2023
EPS came in at -$0.01 surpassing the estimated -$0.15 by +93.33%.
Earnings released on 10 Aug 2023
EPS came in at -$0.33 falling short of the estimated -$0.17 by -94.12%.
Earnings released on 4 May 2023
EPS came in at -$0.16 surpassing the estimated -$0.20 by +20.00%.
Earnings released on 21 Mar 2023
EPS came in at -$0.29 falling short of the estimated -$0.23 by -26.09%.
Earnings released on 3 Nov 2022
EPS came in at -$0.26 surpassing the estimated -$0.31 by +16.13%.
Earnings released on 4 Aug 2022
EPS came in at -$0.60 surpassing the estimated -$0.65 by +7.69%.
Earnings released on 12 May 2022
EPS came in at -$0.72 falling short of the estimated -$0.62 by -16.13%.
Earnings released on 17 Mar 2022
EPS came in at -$1.24 falling short of the estimated -$0.68 by -82.35%.
Earnings released on 4 Nov 2021
EPS came in at -$0.76 falling short of the estimated -$0.72 by -5.56%.
Earnings released on 3 Aug 2021
EPS came in at -$0.74 falling short of the estimated -$0.73 by -1.37%.
Earnings released on 6 May 2021
EPS came in at -$1.30 falling short of the estimated -$0.84 by -54.76%.
Earnings released on 4 Mar 2021
EPS came in at -$0.91 falling short of the estimated -$0.87 by -4.60%, while revenue for the quarter reached $0.00 .
Earnings released on 5 Nov 2020
EPS came in at -$0.87 falling short of the estimated -$0.74 by -17.57%.
XFOR Stock Performance
Access detailed XFOR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.